Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-24-002000
Filing Date
2024-11-14
Accepted
2024-11-14 16:40:36
Documents
54
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q bcli-20240930x10q.htm   iXBRL 10-Q 1133184
2 EX-31.1 bcli-20240930xex31d1.htm EX-31.1 9047
3 EX-31.2 bcli-20240930xex31d2.htm EX-31.2 9531
4 EX-32.1 bcli-20240930xex32d1.htm EX-32.1 6159
5 EX-32.2 bcli-20240930xex32d2.htm EX-32.2 5009
  Complete submission text file 0001410578-24-002000.txt   3995210

Data Files

Seq Description Document Type Size
6 EX-101.SCH bcli-20240930.xsd EX-101.SCH 30220
7 EX-101.CAL bcli-20240930_cal.xml EX-101.CAL 28336
8 EX-101.DEF bcli-20240930_def.xml EX-101.DEF 98741
9 EX-101.LAB bcli-20240930_lab.xml EX-101.LAB 227053
10 EX-101.PRE bcli-20240930_pre.xml EX-101.PRE 186294
57 EXTRACTED XBRL INSTANCE DOCUMENT bcli-20240930x10q_htm.xml XML 496389
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

EIN.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36641 | Film No.: 241463545
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)